Fastest Growing Stocks
ALNY is part of our fastest growing stocks screen, indicating it has high EPS and sales growth.
ALNYLAM PHARMACEUTICALS INC (ALNY) Stock Price & Overview
NASDAQ:ALNY • US02043Q1076
Current stock price
318.85 USD
-9.88 (-3.01%)
At close:
318.85 USD
0 (0%)
After Hours:
The current stock price of ALNY is 318.85 USD. Today ALNY is down by -3.01%. In the past month the price decreased by -0.52%. In the past year, price increased by 35.25%.
ALNY Key Statistics
52-Week Range205.87 - 495.55
Current ALNY stock price positioned within its 52-week range.
1-Month Range299.62 - 335.475
Current ALNY stock price positioned within its 1-month range.
- Market Cap
- 42.286B
- P/E
- 161.04
- Fwd P/E
- 42.73
- EPS (TTM)
- 1.98
- Dividend Yield
- N/A
ALNY Stock Performance
Today
-3.01%
1 Week
-2.84%
1 Month
-0.52%
3 Months
-20.32%
Longer-term
6 Months -30.13%
1 Year +35.25%
2 Years +121.50%
3 Years +60.07%
5 Years +126.71%
10 Years +375.61%
ALNY Stock Chart
ALNY Stock Screens
ALNY currently appears in the following ChartMill screener lists.
Revenue Growth Leaders
ALNY is part of our revenue growth leaders stock screen, indicating it has strong recent and multi-year revenue growth.
ALNY Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ALNY. When comparing the yearly performance of all stocks, ALNY turns out to be only a medium performer in the overall market: it outperformed 52.82% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
ALNY Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ALNY. Both the profitability and the financial health of ALNY get a neutral evaluation. Nothing too spectacular is happening here.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ALNY Earnings
On February 12, 2026 ALNY reported an EPS of 0.82 and a revenue of 1.10B. The company missed EPS expectations (-28.48% surprise) and missed revenue expectations (-8.27% surprise).
Next Earnings DateApr 29, 2026
Last Earnings DateFeb 12, 2026
PeriodQ4 / 2025
EPS Reported$0.82
Revenue Reported1.097B
EPS Surprise -28.48%
Revenue Surprise -8.27%
ALNY Forecast & Estimates
36 analysts have analysed ALNY and the average price target is 454.89 USD. This implies a price increase of 42.67% is expected in the next year compared to the current price of 318.85.
For the next year, analysts expect an EPS growth of 276.83% and a revenue growth 48.81% for ALNY
Analysts
Analysts80
Price Target454.89 (42.67%)
EPS Next Y276.83%
Revenue Next Year48.81%
ALNY Groups
Sector & Classification
ALNY Financial Highlights
Over the last trailing twelve months ALNY reported a non-GAAP Earnings per Share(EPS) of 1.98. The EPS increased by 191.24% compared to the year before.
Income Statements
Revenue(TTM)3.71B
Net Income(TTM)313.75M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.45% | ||
| ROA | 6.32% | ||
| ROE | 39.76% | ||
| Debt/Equity | 3.14 |
Chartmill High Growth Momentum
EPS Q2Q%226.15%
Sales Q2Q%84.95%
EPS 1Y (TTM)191.24%
Revenue 1Y (TTM)65.19%
ALNY Ownership
Ownership
Inst Owners101.56%
Shares132.62M
Float131.71M
Ins Owners0.22%
Short Float %3.32%
Short Ratio3.19
ALNY Latest News, Press Relases and Analysis
2 days ago - By: Chartmill
ALNY Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ALNY
Company Profile
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,500 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.
Company Info
IPO: 2004-05-28
ALNYLAM PHARMACEUTICALS INC
675 W Kendall St
Cambridge MASSACHUSETTS 02142 US
CEO: John M. Maraganore
Employees: 2500
Phone: 16175518200
ALNYLAM PHARMACEUTICALS INC / ALNY FAQ
Can you describe the business of ALNYLAM PHARMACEUTICALS INC?
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,500 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.
What is the current price of ALNY stock?
The current stock price of ALNY is 318.85 USD. The price decreased by -3.01% in the last trading session.
What is the dividend status of ALNYLAM PHARMACEUTICALS INC?
ALNY does not pay a dividend.
What is the ChartMill rating of ALNYLAM PHARMACEUTICALS INC stock?
ALNY has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
On which exchange is ALNY stock listed?
ALNY stock is listed on the Nasdaq exchange.
What is the GICS sector and industry of ALNY stock?
ALNYLAM PHARMACEUTICALS INC (ALNY) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for ALNYLAM PHARMACEUTICALS INC?
ALNYLAM PHARMACEUTICALS INC (ALNY) has a market capitalization of 42.29B USD. This makes ALNY a Large Cap stock.